Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

NCT01766817 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

325

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: BMS-986020
DRUG: Placebo matching with BMS-986020

Sponsor

Bristol-Myers Squibb